Background: Forty percent of low back pain cases are due to intervertebral disc degeneration (IVDD), with mesenchymal stem cells (MSCs) a reported treatment. We utilized an ovine IVDD model and intradiscal heterologous MSCs to determine therapeutic efficacy at different stages of IVDD.
and in tension. 4 The AF and the CEPs encompass the central nucleus pulposus (NP), a proteoglycan-rich tissue which provides the IVD with it's ability to withstand compressive loading. With aging, aggrecan the major IVD proteoglycan, 5 is susceptible to proteolytic degradation 6, 7 resulting in a reduction in NP water-imbibing capacity, loss of hydrodynamic weight-bearing properties, 8 compromised IVD biomechanical competence, loss of NP proteoglycans, 9 diminished disc height and the appearance of clefts and fissures in the AF, symptomatic of a diminished IVD capacity to act as a weight bearing structure. 10 A 10-year global study of 291 major human diseases placed LBP as the number one musculoskeletal disorder in terms of years lived with disability, an estimated 80% of the general population are affected by LBP, its incidence peaks in the fifth and sixth decade. 11 Other studies have emphasized the socioeconomic impact of degenerative disc disease (DDD) and LBP. UK costings for LBP of £12.3 billion, 12 and $9.17 billion for Australia have been published. 13 The American Academy of Pain Medicine published annual costs in 2006 for chronic pain of $560 to 635 billion, with 53% of all chronic pain patients in the USA affected by LBP, 31 million people have LBP at any one time. 14 In 2015, the global point prevalence of activitylimiting LBP of 7Á3% indicated that 540 million people were affected globally by LBP at any one time, and today LBP is now recognized as the number one musckuloskeletal condition and cause of disability world-wide. 11, 15 In 1999, the World Health Organization (WHO) published the IRIS low back pain initiative 16 designating LBP and stem cell research to restore functional IVDs as high priority research areas.
LBP was made a national priority area by the National Health and Medical Research Council (NHMRC) in 2009. 17 Since their discovery in the late 1960s mesenchymal stem cells (MSCs) have been the subject of intense investigation due to their remarkable efficacy in tissue repair. MSCs were originally considered to migrate into sites of injury, where they engrafted, and differentiated into functional cells, resulting in regeneration of damaged or diseased connective tissue. 18 Results over the past few decades from several hundred animal studies and many human clinical trials have challenged this mode of action. There is no doubt that MSCs exhibit a remarkable ability to repair diseased tissues, but it has become increasingly apparent that they do not engraft in enough numbers or for sufficient durations in tissue defects to explain the tissue repair and clinical benefit they provide. A recent positron emission tomography (PET) imaging study showed that MSCs remained viable for 3 weeks when injected into canine IVDs in an annular lesion model of disc degeneration 19 yet beneficial effects with regards to matrix repair and alleviation of LBP were measurable for up to 6 months post operatively (PO). Further modes of action for MSCs in the healing process have therefore been proposed based on the ability of MSCs to enhance resident cell viability and/or proliferation, reduce cell apoptosis, 20, 21 and, in some cases, modulate immune responses. [22] [23] [24] [25] [26] These are due to paracrine effects due to secreted growth factors, cytokines, and hormones from the MSCs and cell-cell interactions mediated through communicating nanotubes, which convey extracellular vesicles containing reparative peptides/proteins, mRNA, and microRNAs. 18 Caplan proposed that stem cells should be renamed
Medicinal Signaling Cells to more accurately reflect how they home in on injured or diseased tissue sites secreting bioactive factors with immunomodulatory and trophic properties which direct the resident cells to undertake the tissue repair process, this may happen long after the MSCs were present in the defect site. 27 The use of MSCs to undertake IVD repair/regeneration is an area which shows much promise [28] [29] [30] with many publications appearing in the literature dealing with animal model based laboratory studies, [31] [32] [33] [34] [35] [36] preclinical studies, 37, 38 clinical trials 39 (Tables 1 and 2 ) and reviews advocating the use of MSCs for disc repair/regeneration. 28, 29, [45] [46] [47] [48] [49] [50] [51] Most pre-clinical studies have treated IVDs with MSCs acutely after induction of disc degeneration, and no direct studies on the relative efficacy of MSCs in different stages of the disease process have been evaluated. This is important given the clinical presentation of patients once pathology is well established and asks the question can MSCs be used to "treat" rather than "prevent" IVDD? While clinical trials have and are being undertaken (Table 2) , the data from the current study will better inform prospective trial design and provide insights as to how patient selection should be made. Based on the findings of the present study there is much to be looked forward to in the therapeutic application of MSCs for the treatment of DDD/LBP.
The aim of the present study was to assess the efficacy of ovine bone marrow stromal stem cells for repair of the degenerate IVD. We used an aggressive ovine model where disc degeneration was induced by a large controlled 6 mm deep by 20 mm wide surgical annular lesion. A wide range of methodologies were used to assess the IVD repair process including testing of the material properties of IVDs using customized in-house developed jigs in an Instron servohydraulic materials testing machine. Pre-and Post-Surgery lateral Xrays were used to calculate disc heights in each of the treatment groups. Biochemical tissue compositional analyses and catabolic and anabolic matrix gene profiling were also used to characterize the degenerative changes in IVDD, and in IVD repair tissue induced by MSC treatment. The histopathology of these IVDs was systematically scored using a recently developed, validated histopathology scoring scheme. 52 A distinguishing feature of this study besides its multidisciplinary evaluations of IVD degeneration and repair processes by 
| Demonstration of MSC authenticity and multipotency
The methodology employed to demonstrate MSC authenticity and 
| Isolation of mesenchymal stem cells

| Demonstration of the multipotency of the mesenchymal stem cell preparation
The actual MSC preparations used on each day for the sheep treatments were tested to ensure that they retained tri-lineage differentiation capacity consistently with other MSC preparations. The surgical model used to induce disc degeneration was as described earlier. 53 Pre-surgical sedation was provided using intravenous 
| Injection of MSCs
In a pilot study, chloromethylbenzamido CellTrackerTM CM-DiI fluorescent dye was used to label MSCs prior to injection. 55 [EA, LA, EST groups respectively (see Figure 1A) ]. Twelve age and sex matched sheep were used as nonoperated, noninjected controls (NOC), these were sacrificed at times equal to 3 or 6 months after the lesion surgery was conducted. L1L2 IVDs were used for histology, L3L4 for gene expression and L5L6 for biomechanics and biochemical analyses (see Figure 1A ,B).
| Spinal imaging
Lateral and dorsal longitudinal plain radiographs were taken pre-and post-lesion surgery, pre-injection, and at the termination of the experiments. Surgical wire was placed through adjacent spinal processes at lesion levels as landmarks on the X-rays to confirm the location of the lesion IVDs. Landmarks were also placed on scanned images of the Xrays for calculation of the disc height index (DHI). 56 
| Biomechanical studies
The L5L6 IVDs and adjacent vertebral body segments were isolated for spinal biomechanical testing using a custom apparatus attached to an Instron servo-hydraulic bi-axial materials testing machine. 57 The specimens were covered by saline-soaked gauze to maintain hydration prior to testing. After all posterior bony elements (dorsal lamina, facet joints) were removed, K-wires were inserted into the vertebral bodies which were then immersed in polymethyl methacrylate for rigid clamping. The functional spinal units were then placed in customized jigs and loaded in flexion-extension, lateral bending or axial rotation with no axial compression at 5 /sec to a torque limit of AE5 Nm for 10 cycles. Torque (Instron dynacell, 50 Nm capacity) and angle data were collected at 20 Hz using the Instron data acquisation system, and the final full cycle was used for analyses. The range of motion (ROM), neutral zone (NZ) and stiffness were measured from cyclic torque-angle curves as previously described. 57 Briefly, ROM was measured as the total angular deflection from maximal positive to minimal negative torque. For NZ and stiffness calculation, first the torqueangle data were fitted with a seventh order polynomial using an in- 
| Compositional analysis of disc tissues
Following biomechanical testing, the IVDs were bisected, then zonally dissected into AF1, AF2 and NP ( Figure 1A) , finely diced and digested with papain overnight at 60 C (20 μL papain suspension, 7.9 mg cysteine per 10 mL PBS containing 10 mM EDTA, pH 7.0). Triplicate aliquots of the solubilized tissues were measured for sulfated glycosaminoglycan (GAG) using 1, 9-dimethylmethylene blue as specified earlier. 58 Tracheal chondroitin sulfate (Sigma C8529) was used as standard. (Figure 4 ) Aliquots of the solubilized tissues were dried by SpeedVac, hydrolysed at 110 C overnight in 6 M HCl, neutralized with 6 M NaOH, and hydroxyproline contents determined on triplicate samples using the dimethylaminobenzaldehyde method of Stegemann and Stalder. 59 
| Histological processing of IVDs
Prior to fixation, all soft and most bony tissue surrounding the IVD were trimmed from the specimens using scalpels and a Dremel router to trim bone and minimize the decalcification time for the specimens.
After en-bloc fixation for 48 hours in 10% neutral-buffered formalin the specimens were decalcified over 8 days in 10% formic acid/5% formalin with constant agitation. Decalcification solution was replaced every 48 hours. Vertical tissue blocks (4 mm) were then taken of the IVD-vertebral bodies perpendicularly through the lesion site ( Figure 1C ). Tissue blocks were dehydrated in graded ethanol solutions, xylene and equilibrated in methyl benzoate prior to embedding in paraffin wax. Microtome sections (4 μm) were cut from the fixed decalcified tissue blocks and attached to Super Frost Plus glass microscope slides (Menzel-Glaser, Germany), de-paraffinized in xylene, and re-hydrated through graded ethanol to water. Table S1 to provide a cumulative histopathology score.
| Toluidine blue staining
| Real-time polymerase chain reaction
The L3L4 IVDs were dissected into AF1, AF2 and NP zones as depicted in Figure 1A Table S2 ). Standard curves were generated using pooled IVD cDNA and relative copy numbers for genes calculated. Sample loadings were normalized on the basis of total RNA content of the samples since we have found that the expression of commonly used housekeeping genes change with disease and are therefore unsuitable for the normalization of such data.
Melt curves were obtained after each qRT-PCR to confirm single PCR products. Details of the qRT-PCR primers used are provided in Table S2 . All samples were examined in triplicate (Figures 8 and 9 ). 
| Statistical methods
| Biochemical compositional analysis of IVD tissues
Analysis of lesion zone GAG levels showed a significant reduction in the AF1 lesion zones of the EA and LA groups but not in the EST treatment group (Figure 3 ). A significant reduction in NP GAG levels in the lesion affected IVDs was normalized by MSC injection in all three treatment groups ( Figure 4A ). Tissue hydroxyproline contents in AF and NP were largely unchanged compared to the NOC levels and were unaffected by the MSC treatment, with the exception of the LA group where the hydroxyproline content was decreased in the MSC discs in both AF zones (data not shown).
| Radiographical changes in lesion IVDs
Disc heights were measured from longitudinal lateral plain radiographs of the lumbar spine prior to surgery and at the end of the study ( Figure 4B ). Loss of disc height was evident in lesion discs treated by PBS injection, with a 15% to 25% reduction compared to pre-surgery 
| Histological examination of IVD tissue sections
Histological inspection of toluidine blue stained IVD sections showed that GAG levels were reduced in lesion IVDs injected with PBS carrier only but were significantly higher in the MSC treated IVDs ( Figure 5 compare plates B, C, D with G, H, I) and IVD heights were also restored. The original IVD lesion propagated through the IVD towards the contralateral AF in the PBS injected IVDs but was largely repaired in the MSC treated IVDs (Figure 5G -I). 
| Biomechanical assessment of lesion IVDs and the effect of MSC injection
| Histopathological scoring of IVDs
The advanced lesion development of the PBS carrier injected IVDs was reflected in higher histopathology scores (Figure 7) . Cystic degeneration and chondroid metaplasia were more advanced in the PBS A diagrammatic representation of the lesion and MSC treatment groups and the main outcomes of this study is provided ( Figure 10) . A point by point summary of the major findings is also provided.
Supplementary figures are also provided to illustrate specific features of the structure and cellular morphology of the normal and degenerate intervertebral discs and to demonstrate features which were used in the histopathological scoring of disc tissues. Table S1 provides the discriminative criteria assessed during histopathological scoring. These terms are described further elsewhere. 52 Figure S2 describes the normal cellular morphology of the AF and NP and cell cloning/clustering observed in the AF in degenerate IVDs. Advanced development of the lesion was also associated with a Resident cells in the NP also had a dissimilar morphology to these groups of cells within these cell nests ( Figure S8 D, E).
| DISCUSSION
| Optimization of the annular lesion for the induction of disc degeneration
In an earlier pilot study, we evaluated a series of progressively deeper and wider annular lesions in our ovine model with a view to producing a destabilizing lesion which would produce accelerated disc degeneration but without prolapse of the NP through the residual AF of the lesion site.
A 6 mm deep 20 mm wide defect was subsequently selected and shown to produce disc degeneration in a 3 to 6 month experimental period. 53 To simplify production of a reproducible annular defect customized scalpel handles and scalpel blades were used as outlined in the present study.
| Selection of the most appropriate MSC injection number to effect a therapeutic response in degenerate IVDs
When deciding on the most appropriate number of MCs for intradiscal injection we evaluated cell numbers which had been used in earlier studies ( Table 1) . We subsequently selected an injection number of 10 million cells per disc. This was similar to cell numbers employed in a number of human clinical trials for the treatment of disc degeneration and the alleviation of low back pain ( Table 2 ).
| Patient selection for prospective therapeutic treatment
An important consideration in any prospective treatment is whether it will be effective during early acute and later acute stages of the Traumatic loading generates discal lesions through cumulative stress fractures of fibrillar components which attach the human IVD to the ring apophysis of the vertebral body. Similar changes have also been observed in the ovine model. 72 Separation of Sharpeys fibers generates rim-lesions pre-disposing the NP to degeneration 73 and these propagate through the AF resulting in radial and circumferential fissures, separation of annular lamellae (de-lamellation) and degenerative changes in the NP and CEPs. 74 These changes include a loss of IVD proteoglycan and tissue hydration, 75 a reduction in disc height, changes in endplate vascularity 76 and vertebral bone density adjacent to the annular lesion 77 and osteoarthritis of the facet joints. 78 An increase in blood vessel and nerve in-growth 79 
| Mode of action of MSCs
Secretion of paracrine factors is now recognized as the primary mechanism by which MSCs induce a regenerative environment to promote tissue healing, 89 cell-to-cell contact has been shown to be of some importance but may not be an essential component. 90, 91 MSCs home to sites of inflammation where they secrete soluble trophic factors such as growth factors, cytokines, and chemokines to promote tissue repair. 92 In-vivo studies show MSC therapy promotes angiogenesis and growth and differentiation of local progenitor cells, prevents fibrosis and apoptosis, attracts immune cells to injury sites, and are immunomodulatory in the local environment. [92] [93] [94] [95] Engraftment of MSCs appears to be unnecessary for a therapeutic effect, and MSCs likely persist through the initial inflammatory phase into the repair and remodeling phases of tissue healing. Adult MSCs from bone marrow, peripheral blood, or adipose tissue, have been or are currently being investigated in over 600 clinical trials in musculoskeletal diseases, degenerative and traumatic neurological diseases, and immune mediated diseases. 96 MSC therapy has been effective at treating several animal models of disease 97, 98 and shown success in human clinical trials. 96 Supplemental figures are supplied to document the range of degenerative features we observed in the present study and to demonstrate the efficacy of MSCs for discal recovery (Figures S2-S8 ).
| Chondroid metaplasia and cystic degeneration in the ovine large lesion DDD model
Extradural cysts similar to the intradiscal cysts observed in the present study have also been observed in the elite athlete. 99 These typically result in compression of spinal ganglia and neurological deficits. IVD cystic degeneration can be imaged by MRI. 100 Cystic degeneration was only observed in the PBS injected IVDs in this study.
Chondroid metaplasia was originally described in the classical work of Hansen (1952) 101 in the nonchondrodystrophic (non-ChD) canine 102, 103 and the lapine IVD. 104 Chondroid metaplasia is considered to be a forerunner to the IVD calcification frequently found in ChD canine breeds. 101, 105 Calcification of the ovine IVD has also been observed 106 suggesting that the ovine merino could be considered a mildly ChD breed. Like the beagle where an inbuilt form of dwarfism has produced characteristic changes in the long bone growth plates, 107 the merino was also originally bred as a long-legged form. A Rambouillet serving ram from France had a major influence on the original Macarthur sheep flock which formed the basis of the Australian merino breed characteristics. 108 Over time this long legged trait has been bred out to a shorter legged "modern" fine wool merino.
So-called "Macarthur" sheep are named after General John Macarthur, 
| The ovine large lesion model of disc degeneration and LBP
Of the animal models which have been used experimentally to produce disc degeneration 81 the ovine large lesion model 53 Even with the benefit of verbal commentary in the clinical assessment of human IVD degeneration, a specific nociceptive cause of LBP is rarely identified despite the impact of a biomechanically deficient IVD being clearly identifiable. The normal IVD is poorly innervated and ingrowth of nerves occurs with IVD degeneration. 79 Paradiscal tissues such as the anterior and posterior longitudinal ligaments, facet joints and vertebral body are all richly innervated and all of these tissues are potential sources of nociception. 109 LBP is an extremely common and debilitating condition experienced by people of all ages thus it is imperative that a better understanding of this disorder be achieved. [110] [111] [112] [113] In 2015, the global point prevalence of activitylimiting LBP of 7Á3% indicated that 540 million people were affected globally by LBP at any one time, LBP is now recognized as the number one musckuloskeletal condition and cause of disability worldwide. 11, 15 The socio-economic impact of LBP on quality of life, associated healthcare costs in its treatment and lost productivity are very significant issues.
As in any animal model, the lack of verbal communication with Human facial recognition software and cloud based technology has also been applied to assess small animal behavior experimentally and is capable of automation. [116] [117] [118] [119] This technology is also beginning to be applied in the identification of livestock in the rural sector and can provide invaluable information on animal appetite habits, water intake and has motion capture capability which can be used as a measure of the habits and health of stock on an individual animal basis. Such were administered into degenerate IVDs 2 weeks later. IVD heights were determined 2, 7 and 10 weeks after lesion induction and the affected IVDs were subjected to histopathological scoring. The authors considered BMMSCs were beneficial for what they considered to be annular repair. 125 Interesting recent developments in bioscaffold design have resulted in production of CS containing scaffolds with the ability to direct MSC cell differentiation in-situ. in the context of tissue repair this can be used to promote the production of matrix components conducive to tissue repair. 127, 128 These bio-scaffolds have yet to be applied to disc and annular repair, however they have properties which would be useful in such applications and are worthy of further examination.
In an extensive review on the use of bioscaffolds and MSCs for Despite promising results with these annular containment products recurrent disc herniations still frequently occurred and were common causes of back pain. The poor healing potential of the AF negatively impacts on the repair of tears in IVDs stabilized using sutures or a surgical containment device, making the disc highly susceptible to retearing. Vascular ingrowth and nociceptive nerves occur in annular defects but these do not penetrate into the NP which is an avascular and aneural tissue. 79, 114, 115 Biological glues may also be useful in the sealing of natural and surgical annular wounds. A novel bio-glue discovered in the Australian frog Notaden benetti is an adhesive exudate from the dorsal skin which ensures sexual union with the male for an extended period to ensure effective fertilization. 131 Its molecular composition and mechanism of action 132 has shown this protein based adhesive 133 is nonimmunogenic, biocompatible, displays elastomeric properties similar to elastin and adhesive properties several-fold that of fibrin glue. Frog glue has been used to re-attach infraspinatus tendon in rotator cuff repair, 134 and bucket handle meniscal tears. 135, 136 New Zealand green lipped mussel and barnacle glues also have strong adhesive properties suitable for orthopedic applications, but await commercialisation. [137] [138] [139] [140] [141] The low number of cells in the mature AF of advanced stages of senescence exclude them as a suitable cell source for the seeding of scaffolds. MSCs are a useful alternative cell type for annular repair and have been isolated from annular tissues of normal and degenerate
IVDs. [142] [143] [144] [145] The cell clustering seen in the vicinity of annular defects is evidence of resident stem cell activity in these tissues. 146 The healing potential of the AF overall however is low with most of its intrinsic healing occurring at its outermost margins. 147 Annular defects which penetrate into the mid and inner AF however do not undergo spontaneous repair and over time these propagate further into the disc and can lead to the development of rim-lesions, de-lamellations, bifurcations, and extension around the NP as far as the contralateral AF with the formation of radial and cirumferential tears. 74 In the present study, the administered MSCs prevented the extension of the initial annular defect and also resulted in healing of the outer annular defect, a significant finding given the large lesion size used in this sheep model.
Reproducing the anisotropic annular structure is a prerequisite for an effective treatment. 148, 149 No studies have so far demonstrated bioscaffolds with mechanical properties and structural features matching those of the native AF. Thus many questions and challenges still remain in the development of effective strategies that lead to regeneration of the damaged AF using a scaffolding approach. However, in the present study MSCs in isolation were effective in the repair of annular defects and biomechanical studies indicated that the MSC treated IVDs had re-attained similar biomechanical characteristics as native IVD tissue. In contrast, in IVDs which received injections of PBS carrier, the controlled outer annular surgical lesion continued to propagate through to the inner AF and NP and the biomechanical properties of these tissues deviated markedly from those of NOC IVD tissues. 
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